Current Epidemiology Reports

, Volume 4, Issue 3, pp 248–257 | Cite as

E-cigarette Use and Indicators of Cardiovascular Disease Risk

  • Rebecca J. SchweitzerEmail author
  • Thomas A. Wills
  • J. Dusty Behner
Cardiovascular Disease (R Foraker, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Cardiovascular Disease


Purpose of Review

The aim is to provide a detailed review of literature from studies examining the relation of electronic cigarette (e-cigarette) use to indicators of risk for cardiovascular disease. In addition to discussing clinical and cell culture studies, we discuss possible mechanisms for the observed effects.

Recent Findings

Studies have compared the effect of e-cigarette use (or vapor) and combustible cigarette smoking on a range of measures. These include heart rate, blood pressure, and vagal tone; aortic stiffness and endothelial function; platelet aggregation and adhesion; expression of genes for antioxidant defense and immune system function; and indices of oxidative stress. The majority of studies found some evidence of a significant risk effect for e-cigarettes, although the evidence was not totally consistent within and between studies. Suggestive evidence also implicates a possible effect of e-cigarettes on inflammation processes. The magnitude of the effect for e-cigarettes was sometimes lower than those found for cigarettes, but several studies showed comparable effects.


The findings overall provide evidence of some risk to the cardiovascular system from e-cigarettes, but conclusions are qualified because each study was heterogeneous in its design and evidence on cardiac morbidity from prospective human studies is not yet available. The studies have helped to identify possible agents and mechanisms for producing risk, including reactive oxygen species and oxidative stress, fine and ultrafine particles, and nicotine. Longitudinal data from clinical and epidemiological studies are needed to clarify these relationships in healthy populations and investigate the impact of e-cigarette use among persons with pre-existing cardiovascular disease.


E-cigarettes Cardiovascular disease Heart disease Vascular disease 


Compliance with Ethical Standards

Conflict of Interest

Rebecca J. Schweitzer and J. Dusty Behner each declare no potential conflicts of interest.

Dr. Wills reports grants from National Cancer Institute during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    National Institute of Drug Abuse. Drug Facts: E-cigarettes. 2015.Google Scholar
  2. 2.
    • Farsalinos KE, Polosa R. Safety evaluation and risk assessment of e-cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014;5:67–87. doi: 10.1177/2042098614524430. Provides a review on the safety of using e-cigarettes for smoking cessation, a topic of importance for regulation and future research. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Schoenborn CA, Gindi RM. E-cigarette use among adults: United States, 2014. NCHS data brief no. 217. US Department of Health and Human Services, CDC: Hyattsville; 2015.Google Scholar
  4. 4.
    Singh T, Arrazola RA, Corey CG, Husten CG, Neff LJ, Homa DM, et al. Tobacco use among middle and high school students—United States, 2011–2015. MMWR Morb Mortal Wkly Rep. 2016;65:361–7. doi: 10.15585/mmwr.mm6514a1.CrossRefPubMedGoogle Scholar
  5. 5.
    Miech RA, Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975–2015: volume 1: secondary school students. Ann Arbor: Institute for Social Research, University of Michigan; 2016.Google Scholar
  6. 6.
    U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general Atlanta, GA: Centers for Disease Control and Prevention.2014.Google Scholar
  7. 7.
    Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from e-cigarettes. Tob Control. 2014;23:133–9. doi: 10.1136/tobaccocontrol-2012-050859.CrossRefPubMedGoogle Scholar
  8. 8.
    Hecht SS, Carmella SG, Kotandeniya D, Pillsbury ME, Chen M, Ransom BW, et al. Evaluation of toxicant and carcinogen metabolites in the urine of e-cigarette users versus cigarette smokers. Nicotine Tob Res. 2015;17:704–9. doi: 10.1093/ntr/ntu218.CrossRefPubMedGoogle Scholar
  9. 9.
    Kosmider L, Sobczak A, Fik M, Knysak J, Zaciera M, Kurek J, et al. Carbonyl compounds in e-cigarette vapors: effects of nicotine solvent and battery output voltage. Nicotine Tob Res. 2014;16:1319–26. doi: 10.1093/ntr/ntu078.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Cobb NK, Abrams DB. The FDA, e-cigarettes, and the demise of combusted tobacco. N Engl J Med. 2014;371:1469–71. doi: 10.1056/NEJMp1408448.CrossRefPubMedGoogle Scholar
  11. 11.
    Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4:116–28. doi: 10.1016/S2213-2600(15)00521-4.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dutra LM, Glantz SA. E-cigarettes and conventional cigarette use among U.S. adolescents: a cross-sectional study. JAMA Pediatr. 2014;168:610–7. doi: 10.1001/jamapediatrics.2013.5488.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pechacek TF, Nayak P, Gregory KR, Weaver SR, Eriksen MP. The potential that electronic nicotine delivery systems can be a disruptive technology: results from a national survey. Nicotine Tob Res. 2016;18:1989–97. doi: 10.1093/ntr/ntw102.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wills TA, Knight R, Williams RJ, Pagano I, Sargent JD. Risk factors for exclusive e-cigarette use and dual e-cigarette use and tobacco use in adolescents. Pediatrics. 2015;135:e43–51. doi: 10.1542/peds.2014-0760.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. E-cigarettes for smoking cessation and reduction. Cochrane Database of Systematic Review 2014:(CD010216). Doi: 10.1002/14651858.CD010216.Google Scholar
  16. 16.
    Soneji S, Barrington-Trimis JL, Wills TA, Leventhal AM, Unger JB, Gibson LA, et al. E-cigarette use and subsequent cigarette smoking among adolescents and young adults: a systematic review and meta-analysis. JAMA Pediatr. 2017; in pressGoogle Scholar
  17. 17.
    Kalkhoran S, Glantz SA. Modeling the health effects of expanding e-cigarette sales in the United States and United Kingdom: a Monte Carlo analysis. JAMA Intern Med. 2015;75:1671–80. doi: 10.1001/jamainternmed.2015.4209.CrossRefGoogle Scholar
  18. 18.
    Vansickel AR, Weaver MF, Eissenberg T. Clinical laboratory assessment of the abuse liability of an e-cigarette. Addiction. 2012;107:1493–500. doi: 10.1111/j.1360-0443.2012.03791.x.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    • Bhatnagar A. E-cigarettes and cardiovascular disease risk: evaluation of evidence, policy implications, and recommendations. Curr Cardiovasc Risk Rep. 2016;10:1–10. doi: 10.1007/s12170-016-0505-6. Importance for an overview of the effects of e-cigarette use on cardiovascualr disease and implications for use and policy. CrossRefGoogle Scholar
  20. 20.
    Williams M, Villarreal A, Bozhilov K, Lin S, Talbot P. Metal and silicate particles including nanoparticles are present in e-cigarette cartomizer fluid and aerosol. PLoS One. 2013;8:e57987. doi: 10.1371/journal.pone.0057987.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    World Health Organization. WHO Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide. Geneva, Switzerland. 2005.Google Scholar
  22. 22.
    U.S. Department of Health and Human Services. E-cigarette use among youth and young adults: a report of the surgeon general. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2016.23.Google Scholar
  23. 23.
    Carnevale R, Sciarretta S, Violi F, Nocella C, Loffredo L, Perri L, et al. Acute impact of tobacco vs e-cigarette smoking on oxidative stress and vascular function. Chest. 2016;150:606–12. doi: 10.1016/j.chest.2016.04.012.CrossRefPubMedGoogle Scholar
  24. 24.
    Csányi G, Miller FJ. Oxidative stress in cardiovascular disease. Int J Mol Sci. 2014;15:6002–8. doi: 10.3390/ijms15046002.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Saremi A, Arora R. Vitamin E and cardiovascular disease. Am J Ther. 2010;17:e56–65. doi: 10.1097/MJT.0b013e31819cdc9a.CrossRefPubMedGoogle Scholar
  26. 26.
    Vlachopoulos C, Ioakeimidis N, Abdelrasoul M, Terentes-Printzios D, Georgakopoulos C, Pietri P, et al. E-cigarette smoking increases aortic stiffness and blood pressure in young smokers. J Am Coll Cardiol. 2016;67:2802–3. doi: 10.1016/j.jacc.2016.03.569.CrossRefPubMedGoogle Scholar
  27. 27.
    Duprez D. Arterial stiffness and cardiovascular disease. E-Journal of Cardiology Practice 2002:1.Google Scholar
  28. 28.
    Yan XS, D’Ruiz C. Effects of using e-cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes. Regul Toxicol Pharmacol. 2015;71:24–34. doi: 10.1016/j.yrtph.2014.11.004.CrossRefPubMedGoogle Scholar
  29. 29.
    Farsalinos K, Cibella F, Caponnetto P, Campagna D, Morjaria JB, Battaglia E, et al. Effect of continuous smoking reduction and abstinence on blood pressure and heart rate in smokers switching to e-cigarettes. Intern Emerg Med. 2016;11:85–94. doi: 10.1007/s11739-015-1361-y.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Antoniewicz L, Bosson JA, Kuhl J, Abdel-Halim SM, Kiessling A, Mobarrez F, et al. E-cigarettes increase endothelial progenitor cells in the blood of healthy volunteers. Atherosclerosis. 2016;255:179–85. doi: 10.1016/j.atherosclerosis.2016.09.064.CrossRefPubMedGoogle Scholar
  31. 31.
    Heiss C, Amabile N, Lee AC, Real WM, Schick SF, Lao D, et al. Brief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol. 2008;51:1760–71. doi: 10.1016/j.jacc.2008.01.040.CrossRefPubMedGoogle Scholar
  32. 32.
    Moheimani RS, Bhetraratana M, Yin F, Peters KM, Gornbein J, Araujo JA, et al. Increased cardiac sympathetic activity and oxidative stress in habitual e-cigarette users: implications for cardiovascular risk. JAMA cardiol. 2017;2:278–84. doi: 10.1001/jamacardio.2016.5303.CrossRefPubMedGoogle Scholar
  33. 33.
    Bhatnagar A. Are e-cigarette users at increased risk for cardiovascular disease? JAMA cardiol. 2017;2:237–8. doi: 10.1001/jamacardio.2016.5550.CrossRefPubMedGoogle Scholar
  34. 34.
    • Cravo AS, Bush J, Sharma G, Savioz R, Martin C, Craige S, et al. A randomised, parallel group study to evaluate the safety profile of an electronic vapour product over 12 weeks. Regul Toxicol Pharmacol. 2016;81:S1–s14. doi: 10.1016/j.yrtph.2016.10.003. Randomized trial showing the effects for smokers substituting e-cigarette use for smoking tobacco cigarettes. CrossRefPubMedGoogle Scholar
  35. 35.
    • Teasdale JE, Newby AC, Timpson NJ, Munafo MR, White SJ. Cigarette smoke but not e-cigarette aerosol activates a stress response in human coronary artery endothelial cells in culture. Drug Alcohol Depend. 2016;163:256–60. doi: 10.1016/j.drugalcdep.2016.04.020. Investigates the stress of heart cells from e-cigarette use. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hom S, Chen L, Wang T, Ghebrehiwet B, Yin W, Rubenstein DA. Platelet activation, adhesion, inflammation, and aggregation potential are altered in the presence of e-cigarette extracts of variable nicotine concentrations. Platelets. 2016;27:694–702. doi: 10.3109/09537104.2016.1158403.CrossRefPubMedGoogle Scholar
  37. 37.
    Putzhammer R, Doppler C, Jakschitz T, Heinz K, Förste J, Danzl K, et al. Vapours of US and EU market leader e-cigarette brands and liquids are cytotoxic for human vascular endothelial cells. PLoS One. 2016;11:e0157337. doi: 10.1371/journal.pone.0157337.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Ji EH, Sun B, Zhao T, Shu S, Chang CH, Messadi D, et al. Characterization of e-cigarette aerosol and its induction of oxidative stress response in oral keratinocytes. PLoS One. 2016;11:e0169380. doi: 10.1371/journal.pone.0169380.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lerner CA, Sundar IK, Yao H, Gerloff J, Ossip DJ, McIntosh S, et al. Vapors produced by e-cigarettes and e-juices with flavorings induce toxicity, oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One. 2015;10:e0116732. doi: 10.1371/journal.pone.0116732.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Martin EM, Clapp PW, Rebuli ME, Pawlak EA, Glista-Baker E, Benowitz NL, et al. E-cigarette use results in suppression of immune and inflammatory-response genes in nasal epithelial cells similar to cigarette smoke. Am J Physiol Lung Cell Mol Physiol. 2016;311:L135–44. doi: 10.1152/ajplung.00170.2016.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hwang JH, Lyes M, Sladewski K, Enany S, McEachern E, Mathew DP, et al. E-cigarette inhalation alters innate immunity and airway cytokines while increasing the virulence of colonizing bacteria. J Mol Med (Berl). 2016;94:667–79. doi: 10.1007/s00109-016-1378-3.CrossRefGoogle Scholar
  42. 42.
    Wu Q, Jiang D, Minor M, Chu HW. E-cigarette liquid increases inflammation and virus infection in primary human airway epithelial cells. PLoS One. 2014;9:e108342. doi: 10.1371/journal.pone.0108342.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Sussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, et al. Exposure to e-cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS One. 2015;10:e0116861. doi: 10.1371/journal.pone.0116861.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    McNeill A, Brose LS, Calder R, Hitchman SC, Hajek P, McRobbie H. E-cigarettes: an evidence update: a report commissioned by Public Health England: Public Health England. 2015.Google Scholar
  45. 45.
    Australian Government: National Health and Medical Research Council. NHMRC CEO Statement: E-cigarettes (E-Cigarettes) 2017.Google Scholar
  46. 46.
    Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: implications for e-cigarette use. Trends Cardiovasc Med. 2016;26:515–23. doi: 10.1016/j.tcm.2016.03.001.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, et al. Expert position paper on air pollution and cardiovascular disease. Eur Heart J. 2015;36:83–93b. doi: 10.1093/eurheartj/ehu458.CrossRefPubMedGoogle Scholar
  48. 48.
    Brook RD. Cardiovascular effects of air pollution. Clin Sci (Lond). 2008;115:175–87. doi: 10.1042/CS20070444.CrossRefGoogle Scholar
  49. 49.
    Mikheev VB, Brinkman MC, Granville CA, Gordon SM, Clark PI. Real-time measurement of e-cigarette aerosol size distribution and metals content analysis. Nicotine Tob Res. 2016;18:1895–902. doi: 10.1093/ntr/ntw128.CrossRefPubMedGoogle Scholar
  50. 50.
    Zhang Y, Sumner W, Chen DR. In vitro particle size distributions in electronic and conventional cigarette aerosols suggest comparable deposition patterns. Nicotine Tob Res. 2013;15:501–8. doi: 10.1093/ntr/nts165.CrossRefPubMedGoogle Scholar
  51. 51.
    D'Ruiz CD, Graff DW, Yan XS. Nicotine delivery, tolerability and reduction of smoking urge in smokers following short-term use of one brand of e-cigarettes. BMC Public Health. 2015;15:991. doi: 10.1186/s12889-015-2349-2.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med. 1976;295:573–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Benowitz NL, Fraiman JB. Cardiovascular effects of e-cigarettes. Nat Rev Cardiol. 2017. Epub ahead of print. Doi:  10.1038/nrcardio.2017.36.
  54. 54.
    Piano MR, Benowitz NL, Fitzgerald GA, Corbridge S, Heath J, Hahn E, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation. 2010;122:1520–44. doi: 10.1161/CIR.0b013e3181f432c3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Rebecca J. Schweitzer
    • 1
    Email author
  • Thomas A. Wills
    • 2
  • J. Dusty Behner
    • 2
  1. 1.University of Hawaii Manoa, Office of Public Health StudiesHonoluluUSA
  2. 2.University of Hawaii Cancer CenterHonoluluUSA

Personalised recommendations